Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.
Raymond, E Niccoli, P Castellano, D Hammel, P Raoul, J Vinik, A Bang, Y Lee, S Borbath, I
Raymond, E
Niccoli, P
Castellano, D
Hammel, P
Raoul, J
Vinik, A
Bang, Y
Lee, S
Borbath, I
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover. 2016, 34(4) J Clin Oncol